Scientific Update.

Slides:



Advertisements
Similar presentations
Treatment for Adolescents With Depression Study (TADS)
Advertisements

Introduction. Adult ADHD in the Real World: From Clinical Trials to Clinical Practice.
Module 3 Indications for Antipsychotics Bipolar Disorder
This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.
Major Depressive Disorder: Latest Clinical Update
Key Issues in Depression: Highlights From APA 2016
Clinical Trials in IBD.
A Review of the Critical Role of Imaging in Primary Liver Malignancy
This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States.
MR Imaging in Children.
Bipolar Depression Pharmacotherapy: Part 1
Advances in Managing Inhibitors in Patients With Hemophilia A
Bipolar Disorder: Latest Clinical Update
5 Things NPs and PAs Need to Know About Tardive Dyskinesia
Updates on Emerging GLP-1 Receptor Agonists
Progression After Cancer Immunotherapy in Advanced NSCLC
From the 2015 Conferences to the Clinic
From Conference to the Clinic
COPD Management.
Managing Hereditary Angioedema
Updates in Management of Atopic Dermatitis From Real Patient Cases
Please consider these data to be preliminary until they have been published in peer-reviewed journals.
PARP Inhibitors and Cancer: What Do You Need to Know?
Surveying the Safety of NOACs in the Real World
The Mood Disorder Spectrum
Aligning Patients and Clinicians: Optimizing Outcomes in Metastatic NSCLC.
What Would You Do in This Case of MDD?
Chronic Idiopathic Urticaria
Program Goals. The Role of Chemotherapy in Improving Quality of Life in Advanced NSCLC.
Asthma and Atopic Comorbidities
The Evolving Role of Immunotherapy in NSCLC
Managing Depression in Bipolar I Disorder
Addressing Challenges in Factor VIII Inhibitors in Children With Hemophilia.
Advanced Lung Cancers: What's on the Horizon?
Multidisciplinary Perspectives on Interstitial Lung Diseases
Next-Gen Psoriasis Therapies:
Evaluating Next-Generation BTK Inhibitors
Hyperhidrosis Is Burdensome!
Gene Therapy: Past, Present, and Future
Therapeutic Approaches to the Management of EDS in OSA
Essential Concepts in the Use of Immunotherapies in Bladder Cancer
Immunotherapy for cSCC
Novel Approaches in T1D Management
Extending Treatment for Thrombosis: What’s the Right Choice?
Perspectives on the Impact of Inflammation in OA
Pseudobulbar Affect or Psychiatric Condition?
Impactful Data in TD That Can Guide Treatment Decisions
Updates in Neurogenic Orthostatic Hypotension
Lurasidone Flavio Guzmán, MD.
New Recommendations on How to Stage Hidradenitis Suppurativa
New Data on Emerging Treatments for Psoriasis
When Is Biologic Therapy Appropriate for HS?
Improving Outcomes in Psoriatic Arthritis
Updates in the Management of Acute Promyelocytic Leukemia
Advances in Immunotherapy for Peanut Allergy
Immune Checkpoint Inhibitors in Lung Cancer
Battling the Flu: Latest Advances in the Influenza Treatment Arsenal
Guide to Atopic Dermatitis
The Burden of Psoriasis:
Patient Questions and Expert Answers in Psoriasis:
Patient and Clinician Perspectives on Preventive Therapy for Migraine
New Trends in Treatment for Major Depressive Disorder
Novel Concepts in the Management of RCC
Optimizing Outcomes in mRCC: Finding the Balance of Immune Inhibition
This program will include a discussion of off-label treatment or use of investigational agents not approved by the FDA for use in the US, and data that.
This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.
Immune Checkpoint Inhibitors in Lung Cancer
Widening the Options for Major Depressive Disorder
Expert Perspectives.
Psoriatic Arthritis.
Presentation transcript:

Scientific Update

This program will include a discussion of off-label treatments not approved by the FDA for use in the US.

Introduction and Recap

Nonpharmacologic Interventions

Treatment of Bipolar Depression

FDA-Approved Agents for Bipolar Disorder in Children and Adolescents

Impact of Age on Antidepressant-Related Adverse Effects in Youth at Risk for Bipolar Disorder

Antidepressants for Depression Associated With Bipolar Disorder in Youth

Negative Reactions to Antidepressants Among Youth With Bipolar Disorder

Children's Depression Rating Scale

Lithium for Youth With Depression Associated With Bipolar I Disorder: An Open-Label Study

Lamotrigine for Youth With Bipolar Spectrum Disorders: An Open-Label Study

Quetiapine in Youth With Depressive Episodes Associated With Bipolar I Disorder

Quetiapine XR in Youth With Acute Bipolar Depression

OFC for Youth Aged 10 to 17 Years With Bipolar Depression

A Double-Blind, Placebo-Controlled Trial of Lurasidone for Youth With Bipolar Depression

Study Demographics and Primary Outcome Measure: CDRS-R Total Score

Most Common AEs* and Trial Safety Summary

Results of 2-Year Open-Label Study: Efficacy and Safety

Roles of Clinicians and the Community When Managing Pediatric Bipolar Depression

Concluding Remarks

Abbreviations

Abbreviations (cont)